DXCM · News · 20260805N

Competition and Market Share

DEXCOM INC · 2026-08-05 · Importance 51 · Surprise 64

Senseonics reported approximately 120% year-over-year revenue growth to $14.5 million in the second quarter, driven primarily by U.S. expansion and increased adoption of its Eversense continuous glucose monitoring system. The result indicates accelerating demand for an alternative CGM platform in the U.S. market. Senseonics is also advancing its Gemini product, with a 510(k) submission targeted for the first quarter of 2027, potentially adding future competitive pressure in CGM.

Key facts

• Insulet's stock tumbled 12.1% after Q2 results, and that downturn also impacted competitors Tandem Diabetes and Dexcom, sending their shares lower. source
• Seeking Alpha reported that Insulet's Q2 results, which included a lowered full-year revenue outlook, caused its stock to hit a 52-week low and also impacted competitors Tandem Diabetes and Dexcom, sending their shares lower. source
• DexCom shares fell 4.92% on Wednesday to close at $82.66, marking its second consecutive day of losses. source
• Argus's analyst report dated August 4, 2026 noted Dexcom's current stock price as $84.75. source